573 related articles for article (PubMed ID: 10815616)
21. Release of interleukin-6 and its soluble receptors by activated peripheral blood monocytes is elevated in hypocholesterolemic hemodialysis patients.
Tsirpanlis G; Chatzipanagiotou S; Boufidou F; Kordinas V; Alevyzaki F; Zoga M; Kyritsis I; Ioannou D; Fatourou A; Nicolaou C
Am J Nephrol; 2005; 25(5):484-90. PubMed ID: 16127269
[TBL] [Abstract][Full Text] [Related]
22. Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients.
Kovacs E
Biomed Pharmacother; 2001 Sep; 55(7):391-6. PubMed ID: 11669502
[TBL] [Abstract][Full Text] [Related]
23. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
24. Increased levels of IL-6, sIL-6R, and sgp130 in the aqueous humor and serum of patients with diabetic retinopathy.
Chen H; Zhang X; Liao N; Wen F
Mol Vis; 2016; 22():1005-14. PubMed ID: 27563232
[TBL] [Abstract][Full Text] [Related]
25. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure.
Hirota H; Izumi M; Hamaguchi T; Sugiyama S; Murakami E; Kunisada K; Fujio Y; Oshima Y; Nakaoka Y; Yamauchi-Takihara K
Heart Vessels; 2004 Sep; 19(5):237-41. PubMed ID: 15372299
[TBL] [Abstract][Full Text] [Related]
26. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family.
Montero-Julian FA; Brailly H; Sautès C; Joyeux I; Dorval T; Mosseri V; Yasukawa K; Wijdenes J; Adler A; Gorin I; Fridman WH; Tartour E
Clin Cancer Res; 1997 Aug; 3(8):1443-51. PubMed ID: 9815830
[TBL] [Abstract][Full Text] [Related]
27. The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth.
Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
Int Immunol; 1996 Apr; 8(4):595-602. PubMed ID: 8722639
[TBL] [Abstract][Full Text] [Related]
28. High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130.
Pignatti P; Ciapponi L; Galle P; Hansen MB; Massa M; Meazza C; Paonessa G; Novick D; Ciliberto G; Martini A; De Benedetti F
Clin Exp Immunol; 2003 Feb; 131(2):355-63. PubMed ID: 12562400
[TBL] [Abstract][Full Text] [Related]
29. Distinctive pro-inflammatory gene signatures induced in articular chondrocytes by oncostatin M and IL-6 are regulated by Suppressor of Cytokine Signaling-3.
Liu X; Liu R; Croker BA; Lawlor KE; Smyth GK; Wicks IP
Osteoarthritis Cartilage; 2015 Oct; 23(10):1743-54. PubMed ID: 26045176
[TBL] [Abstract][Full Text] [Related]
30. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
Beguin Y; Lampertz S; De Groote D; Igot D; Malaise M; Fillet G
Leukemia; 1993 Dec; 7(12):2019-25. PubMed ID: 8255102
[TBL] [Abstract][Full Text] [Related]
31. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.
Aparicio-Siegmund S; Garbers Y; Flynn CM; Waetzig GH; Gouni-Berthold I; Krone W; Berthold HK; Laudes M; Rose-John S; Garbers C
Am J Physiol Endocrinol Metab; 2019 Aug; 317(2):E411-E420. PubMed ID: 31237452
[TBL] [Abstract][Full Text] [Related]
32. Endotoxin down-regulates monocyte and granulocyte interleukin-6 receptors without influencing gp130 expression in humans.
Dekkers PE; Juffermans NP; ten Hove T; de Jonge E; van Deventer SJ; van der Poll T
J Infect Dis; 2000 Mar; 181(3):1055-61. PubMed ID: 10720531
[TBL] [Abstract][Full Text] [Related]
33. Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage.
Jasiewicz M; Knapp M; Waszkiewicz E; Ptaszynska-Kopczynska K; Szpakowicz A; Sobkowicz B; Musial WJ; Kaminski KA
Cytokine; 2015 Dec; 76(2):187-192. PubMed ID: 26163998
[TBL] [Abstract][Full Text] [Related]
34. [Study of interleukins and their soluble receptors in B-cell chronic lymphatic leukemia].
Parfieńczyk A; Kiersnowska-Rogowska B; Rogowski F
Pol Merkur Lekarski; 2004 Jan; 16(91):22-5. PubMed ID: 15074015
[TBL] [Abstract][Full Text] [Related]
35. [Examination and evaluation of sIL-6R, sgp130 in serum in patients with chronic hepatopathy].
Shang J; Xu Y; Zhang H
Zhonghua Gan Zang Bing Za Zhi; 2000 Apr; 8(2):87-8. PubMed ID: 10861111
[TBL] [Abstract][Full Text] [Related]
36. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk.
Pulsatelli L; Boiardi L; Pignotti E; Dolzani P; Silvestri T; Macchioni P; Cantini F; Salvarani C; Facchini A; Meliconi R
Arthritis Rheum; 2008 Aug; 59(8):1147-54. PubMed ID: 18668607
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases.
Nikolaus S; Waetzig GH; Butzin S; Ziolkiewicz M; Al-Massad N; Thieme F; Lövgren U; Rasmussen BB; Reinheimer TM; Seegert D; Rosenstiel P; Szymczak S; Schreiber S
Int J Colorectal Dis; 2018 Jul; 33(7):927-936. PubMed ID: 29748708
[TBL] [Abstract][Full Text] [Related]
38. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis.
Hasegawa M; Sato S; Ihn H; Takehara K
Rheumatology (Oxford); 1999 Jul; 38(7):612-7. PubMed ID: 10461473
[TBL] [Abstract][Full Text] [Related]
39. Effects of Viscum album extract therapy in patients with cancer: relation with interleukin-6, soluble interleukin-6 receptor, and soluble gp130.
Kovacs E
J Altern Complement Med; 2004 Apr; 10(2):241-6. PubMed ID: 15165404
[TBL] [Abstract][Full Text] [Related]
40. Similar serum levels of IL-6 and its soluble receptors in patients with HCV-related arthritis and rheumatoid arthritis: a pilot study.
Riccio A; Postiglione L; Sabatini P; Linvelli M; Soriente I; Sangiolo MG; Amato P; Tarantino G
Int J Immunopathol Pharmacol; 2012; 25(1):281-5. PubMed ID: 22507342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
